The endTB Study Group is the group that is responsible for the endTB Observational Study (NCT02754765), which includes more than 2700 patients started on bedaquiline and delamanid containing regimens in 17 countries. Organized by country, this is a list of doctors, nurses, data managers, pharmacists, social workers, administrators and others who have spent many hours collecting and cleaning data, working closely with patients, and ensuring that the endTB Observational Study works smoothly in every aspect of its complex existence.
This MSF Access Campaign report – now in its sixth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs in the framework of the new 2019 WHO DR-TB guidelines.
We provide detailed pricing profiles of key DR-TB drugs available on the Global TB Drug Facility website and estimated prices of DR-TB regimens recommended by WHO in programmatic or operational research frameworks.
This report was produced using among others endTB observational cohort data.
This MSF Access Campaign report – now in its fifth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.
We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.
This report was produced with endTB's support.
Geneva, November 2018
Researchers from endTB participated in the WHO Global Consortium to share updated results and the study’s implementation practices, in addition to evidence to support the transition, operationalization, and scale-up of new MDR-TB guidelines.
Pharmacovigilance forms and other resources for staff on endTB sites.
